Miguel Regueiro, MD
A Miss for FMT in Ulcerative Colitis, Additional Upadacitinib Benefits in Crohn’s
This month’s report looks at two distinct issues: fecal microbiota transplantation and upadacitinib.
SEPTEMBER 27, 2024
FDA Approves Guselkumab for UC
The FDA has approved guselkumab (Tremfya, Janssen) for patients with moderately to severely active ulcerative ...
SEPTEMBER 12, 2024
Subcutaneous Infliximab or Vedolizumab For Maintenance Therapy in IBD; Fast-Acting Upadacitinib in Crohn’s
In this month’s The Regueiro Report, I highlight two studies on medications to treat inflammatory bowel ...
JUNE 27, 2024
Advanced Therapies for IBD Do Not Appear To Raise Thrombotic Risk
In patients with IBD, neither biologics nor small molecule targeted therapies increase the risk for major adverse ...
DECEMBER 30, 2023
More Insight Into Anti-Interleukins
This month’s report focuses on the anti-interleukin treatments for inflammatory bowel disease, specifically ...
SEPTEMBER 21, 2023
Racial Disparities Seen in Use of IBD Medical Therapy
Black patients with IBD are less likely to be treated with certain therapies than white IBD patients, according to ...
JANUARY 17, 2023
